ArticleCureus2024
Association of Liver Biomarkers With Jaundice in Patients With Gastrointestinal Complications: An Observational Retrospective Cohort Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionJaundice is a state of disease in liver function often along with gastrointestinal (GI) complications primarily characterized by hyperbilirubinemia. Other tests regarding liver function are often used besides bilirubin as during any liver complications biomarkers such as alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT), aspartate aminotransferase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), and many other biomarkers even total protein metabolism might get disrupted and get released in the blood. However, no comparison or association among those biomarkers was determined in a cohort. Method: In this observational retrospective cohort study, we investigated the levels of different liver biomarkers and tried to compare their differences and correlations in jaundice patients with GI complications. We examined nine different biomarkers where, primarily, the jaundice was confirmed through the total bilirubin test and further categorized and analyzed them.
resultAmong the 91 patients of the study cohort after bilirubin (n=91) and conjugated bilirubin (n=88) levels, we found that enhanced globulin (n=79) levels were the most dominant among the cohort followed by unconjugated bilirubin (n=76), albumin (n=72), and total protein (n=71). On the other hand, a high ALP level was determined in the lowest number of the population (n=22). Regarding the category of men and women, similar findings were observed with a slight variation as the number of included female patients was approximately six times higher than that of male patients. In the case of age groups, similar observations were determined with some slight variation, as most of the patients were found to be over 40 years of age.
conclusionBesides bilirubin, globulin can be a promising biomarker to diagnose jaundice, especially in patients with GI complications. It may also help to indicate the presence of undiagnosed or unsuspected jaundice in patients with gastrointestinal problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.